Actinogen: Presentation, CEO Sessions Brisbane

Company Presentations

by Carolyn Herbert

Actinogen Limited (ASX:ACW) CEO Dr Bill Ketelbey told the conference ‘Alzheimer’s disease is emerging as one of the most significant health challenges of our time. A person develops Alzheimer’s disease almost every minute in the US.’
Dr Ketelbey outlined the development and milestones of the company’s lead drug Xanamem, most recently the completion of a second Phase I trial.
The biotechnology company is now preparing for a Phase II trial. The trial will be a double blind, randomised, placebo controlled study to assess the safety, tolerability and efficacy of Xanamem in participants with mild Alzheimer's disease.

Carolyn Herbert

Finance News Network
Carolyn joined FNN in August 2015 as the Head of News and also presented the Market at Midday and the Market Wrap. With more than five years of broadcast journalism experience, Carolyn has worked as a finance anchor on the Sky News Business channel and as an anchor and reporter for ABC News. She is also a qualified corporate lawyer specialising in IPOs, takeovers and mergers and acquisitions.